Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Clinical-stage immunotherapy company developing CAR-T cell therapeutics for oncology, focused on engineered T cell cancer treatments.
CARsgen Therapeutics is a clinical-stage immunotherapy company based in Shanghai, China, that focuses on discovering, developing, and commercializing chimeric antigen receptor T-cell (CAR-T) therapeutics. The organization engineers specialized T cells to target and eliminate malignant tumors, advancing a diverse pipeline of oncology treatments through various phases of clinical trials. Operating within the global biotechnology sector, the firm has raised significant capital to fund its proprietary research programs, including an approximately $400 million initial public offering on the Hong Kong Stock Exchange. The company's executive leadership team includes Chief Medical Officer Raffaele Baffa and Senior Vice President of Business Development Leigh Hsu, who collectively guide the organization's clinical and commercial development strategies. Operating as a publicly traded enterprise today, the biotechnology firm CARsgen Therapeutics was officially established in 2014 by primary co-founder Zonghai Li.
CARsgen Therapeutics has raised $276.0M across 3 funding rounds.
CARsgen Therapeutics has raised $276.0M in total across 3 funding rounds.
CARsgen Therapeutics has raised $276.0M in total across 3 funding rounds.
CARsgen Therapeutics's investors include Loyal Valley Capital, Lilly Asia Ventures, Shiyu Capital, Summer Capital, Photon Fund, Jolly Innovation Ventures, Chi Hoon Hyun, JIC GenesisFountain Healthcare Ventures, Kaitai Capital.
CARsgen Therapeutics has raised $276.0M across 3 funding rounds. Most recently, it raised $186.0M Series C in November 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 3, 2020 | $186M Series C | Loyal Valley Capital | Lilly Asia Ventures, Shiyu Capital, Summer Capital | Announced |
| Mar 2, 2018 | $60M Series B Plus | Photon Fund | — | Announced |
| Jan 25, 2016 | $30M Series B | Jolly Innovation Ventures, CHI Hoon Hyun | JIC Genesisfountain Healthcare Ventures, Kaitai Capital | Announced |